About Us

For Media Inquiries, Please Contact:

Jordan Berman
Vice President,
Global Corporate Communications

Apotex Inc.
  150 Signet Drive
North York,
ON, M9L 1T9
Canada
  416-401-7487
  Email

Press Center

March 20, 2020

Apotex Donates Hydroxychloroquine for a Clinical Study to Prevent Infection From Covid-19 With Front Line Health Care Workers
February 4, 2020

Voluntary Recall of APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) 500mg Tablets.
December 5, 2019

Apotex Releases New Supply of Tamoxifen into Canadian Market

Canada’s leading generic drug manufacturer, Apotex, announced today that its first shipment of the drug tamoxifen has been released to the Canadian market. Additional releases are scheduled for December 2019 and January 2020.
June 1, 2018

Apotex Builds Momentum in Canada's Biosimilar Market After World's First Approval

Health Canada Leads the Way by Approving the First-Ever Pegfilgrastim Biosimilar in any Highly Regulated World Market
September 1, 2017

VOLUNTARY NATIONWIDE RECALL: One lot of APO-NITROGLYCERIN (Nitroglycerin Sublingual Spray) Apotex standard, 0.4MG/Metered dose due to possibility of non-spraying pump
February 9, 2017

VOLUNTARY NATIONWIDE RECALL: One lot of ALYSENA™ 28 (Levonorgestrel and Ethinyl Estradiol tablets, USP 100 mcg/20 mcg) Due to Possibility of Broken/Chipped Tablets
March 31, 2016

Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets

Apobiologix^®, a Division of Apotex Inc., today launched Grastofil^®, its first subsequent entry biologic (SEB) approved in Canada.
March 24, 2016

Apotex Launches First Generic Version of Merck's Nasonex®

Apotex Inc. announced today that it has launched the first generic version of Merck's Nasonex^® nasal spray (mometasone furoate monohydrate) in the United States.